Additionally, GLI inhibitors are more suitable candidates for treating noncanonical Hh pathway-associated cancers that are not dependent on SMO input for GLI activation (discussed in Section 3.1.1 and Section 3.1.2). The gene discussed is GLI1; the disease is cancer.